List view / Grid view
26 February 2016 | By Victoria White
The LATTE-2 study showed that a regimen of two investigational long-acting, intramuscular (IM) formulations of HIV medicines had comparable antiviral activity to 3-drug oral antiretroviral therapy in HIV-1 infected adults...
8 January 2016 | By Victoria White
ViiV Healthcare has formalised its collaboration with Janssen for the Phase III investigation and commercialisation of the injectable formulations of cabotegravir and rilpivirine...
2 December 2015 | By Victoria White
Johnson & Johnson has announced four new public-private partnerships to significantly reduce the burden of HIV incidence, especially among adolescent girls...
3 November 2015 | By Victoria White
Results from the study show that cabotegravir and rilpivirine were comparable in maintaining viral suppression rates to a three drug oral regimen...
21 August 2015 | By Victoria White
An MAA for an investigational regimen that combines emtricitabine, tenofovir alafenamide and rilpivirine (R/F/TAF) has been fully validated by the EMA...
